urea has been researched along with oxidopamine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brotchie, JM; Fox, SH; Moser, B | 1 |
| Hashimoto, S; Khotib, J; Miyatake, M; Nagumo, Y; Nakamachi, T; Narita, M; Sakurai, T; Shioda, S; Suzuki, T; Yanagisawa, M | 1 |
| Korkach, IuP; Kotsiuruba, AV; Sahach, VF; Talanov, SA | 1 |
| Bonhaus, DW; McFarland, K; Price, DL | 1 |
| Chen, AQ; Chen, H; Chen, L; Chen, WF; Chen, XY; Liu, HX; Liu, HY; Pang, YY; Sheng, Q; Wang, Y; Xue, Y; Yang, YT | 1 |
| Agrawal, S; Kumari, N; Kumari, R; Luthra, PM; Sharma, D | 1 |
6 other study(ies) available for urea and oxidopamine
| Article | Year |
|---|---|
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagonists; Indoles; Kynurenic Acid; Locomotion; Male; Microinjections; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Substantia Nigra; Sympatholytics; Urea | 1998 |
Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine.
Topics: Animals; Benzoxazoles; Conditioning, Operant; Desipramine; Dopamine; Female; Haloperidol; Injections, Intraventricular; Injections, Subcutaneous; Intracellular Signaling Peptides and Proteins; Limbic System; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Microdialysis; Microinjections; Morphine; Motor Activity; Naphthyridines; Neuropeptides; Nucleus Accumbens; Orexins; Oxidopamine; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Reward; RNA, Messenger; Tyrosine 3-Monooxygenase; Urea; Ventral Tegmental Area | 2006 |
[Oxidative stress in the cardiovascular system of rats with chronic deficiency of cerebral dopamine].
Topics: Animals; Cardiovascular System; Cerebral Cortex; Corpus Striatum; Dopamine; Erythrocytes; Lipid Peroxidation; Male; Malondialdehyde; Mitochondria, Heart; Myocardium; Neurons; Oxidative Stress; Oxidopamine; Rats; Rats, Wistar; Reactive Oxygen Species; Substantia Nigra; Urea; Uric Acid | 2009 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea | 2011 |
Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats.
Topics: Action Potentials; Animals; Benzoxazoles; Globus Pallidus; Haloperidol; Male; Naphthyridines; Neurons; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Oxidopamine; Parkinson Disease; Postural Balance; Rats; Rats, Wistar; Urea | 2016 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats, Wistar; Reactive Oxygen Species; Rotarod Performance Test; Thiazoles; Tyrosine 3-Monooxygenase; Urea | 2018 |